Pharmacological applications of inorganic complexes

General Pharmacology

Volumn 32, Issue 5, 1999, Pages 525-540

  Bakhtiar, Ray ^a   Ochiai, Ei Ichiro ^b  

^a STEVENS INSTITUTE OF TECHNOLOGY   (United States)

^b JUNIATA COLLEGE   (United States)

Author keywords

Bio organometallic chemistry; Bioinorganic chemistry; Metabolism; Metal complexes; Pharmacology

Indexed keywords

ARSENIC DERIVATIVE; ARSPHENAMINE; BLEOMYCIN IRON; CARBOPLATIN; CISPLATIN; GOLD COMPLEX; LITHIUM SALT; LOBAPLATIN; METAL COMPLEX; NITROPRUSSIDE SODIUM; PLATINUM DERIVATIVE; TRACER; VANADIUM DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER; CANCER THERAPY; DIABETES MELLITUS; HUMAN; HYPERTENSION; MANIC DEPRESSIVE PSYCHOSIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; SYPHILIS;

ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; ANTIRHEUMATIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; INORGANIC CHEMICALS; PLATINUM COMPOUNDS;

EID: 0032919452     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00223-7     Document Type: Review

References (93)

1. Barth R.F., Soloway A.H., Brugger R.M. Boron neutron capture therapy of brain tumors. past history, current status, and future potential Cancer Invest. 14:1996;534-550.
2. Bates J.N., Baker M.T., Guerra R. Jr., Harrison D.G. Nitric oxide generation from nitroprusside by vascular tissue. Biochem Pharmac. 42:1991;S157-S165.
3. Berg T., Vandersteen A.M., Janda K.D. High-throughput synthesis and direct screening for the discovery of novel hydrolytic metal complexes. Biorg Med Chem Lett. 8:1998;1221-1224.
4. Bernersprice S.J., Sadler P.J. Coordination chemistry of metallodrugs. insight into biological speciation from NMR spectroscopy Coord Chem Rev. 151:1996;1-40.
5. Bhanot S., Michoulas A., McNeill J.H. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol Cell Biochem. 153:1995;205-209.
6. Bowden C.L. Predictors of response to divalproex and lithium. J Clin Psychiatry. 56:1995;25-30.
7. Briviba K., Tamler R., Klotz L.-O., Engman L., Cotgreave I.A., Sies H. Protection by organotellurium compounds against peroxynitrite-mediated oxidation and nitration reactions. Biochem Pharmac. 55:1998;817-823.
8. Calamai P., Carotti S., Guerri A., Mazzei T., Messori L., Mini E., Orioli P., Speroni G.-P. Cytotoxic effects of gold (III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. Anti-Cancer Drug Des. 13:1998;67-80.
9. Carpinelli P., Bartolucci S., Ruffo F. Synthesis and biological activity of five-coordinate platinum (II) complexes including organotin fragments. Anti-Cancer Drug Des. 10:1995;43-49.
10. Chakraborty A.K., Majumder H.K. Mode of action of pentavalent antimonials. specific inhibition of type I DNA topoisomerase of Leishmania donovani Biochem Biophys Res Commun. 152:1988;605-611.
11. Christodoulou C., Ferry D., Fyfe D., Young A., Doran J., Sass G., Eliopoulos A., Sheehan T., Kerr D.J. Phase I clinical trial of titanocene dichloride (TD) with pharmacokinetic analysis. Proc Am Assoc Cancer Res. 38:1997;1495. Abstract.
12. Coderre J.A., Elowitz E.H., Chadha M., Bergland R., Capala J., Joel D.D., Liu H.Y.B., Slatkin D.N., Chanana A.D. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons. trial design and early clinical results J Neuro-Oncol. 33:1997;141-152.
13. Dawe R.S., Naidoo D.K., Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol. 137:1997;826-827.
14. Desai M.C., Zuckermann R.N., Moos W.H. Recent advances in the generation of chemical diversity libraries. Drug Dev Res. 33:1994;174-188.
15. Dilworth J.R., Parrott S.J. The biomedical chemistry of technetium and rhenium. Chem Soc Rev. 27:1998;43-55.
16. Dittes U., Vogel E., Keppler B.K. Overview on bismuth (III) and bismuth (V) complexes with activity against Helicobacter pylori. Coord Chem Rev. 163:1997;345-364.
17. Domingo J.L., Gomez M., Sanchez D.J., Llobet J.M., Corbella J., Keen C.L. Normalization of hyperglycemia by vanadate or vanadyl treatment in diabetic rats. Trace Elem Electrolytes. 11:1994;16-22.
18. Duncan J.S. Imaging and epilepsy. Brain. 120:1997;339-377.
19. Ecker D.J., Crooke S.T. Combinatorial drug discovery. which methods will produce the greatest value? Bio-Technology. 13:1995;351-360.
20. Edelman R.R., Warach S. Magnetic resonance imaging. 1 N Engl J Med. 328:1993;708-716. a.
21. Edelman R.R., Warach S. Magnetic resonance imaging. 2 N Engl J Med. 328:1993;785-791. b.
22. Engman L., Cotgreave I., Angulo M., Taylor C.W., Paine-Murrieta G.D., Powis G. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anticancer Res. 17:1997;4599-4606.
23. 3]. synthesis and liposomal delivery to murine tumors Proc Natl Acad Sci USA. 91:1994;3029-3033.
24. Fink M. Combining electroconvulsive-therapy and drugs. a review of safety and efficacy CNS Drugs. 1:1994;370-376.
25. Franco M.A., Barbosa A.C., Rath S., Dorea J.G. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg. 52:1995;435-437.
26. Go K.G., Bulte J.W.M., de Ley L., The T.H., Kamman R.L., Hulstaert C.E., Blaauw E.H., Ma L.D. Our approach towards developing a specific tumour-targeted MRI contrast agent for the brain. Eur J Radiol. 16:1993;171-175.
27. 2 with calf thymus DNA. FEBS Lett. 322:1993;291-294.
28. Harding M.M., Prodigalidad M., Lynch M.J. Organometallic anticancer agents. 2. Aqueous chemistry and interaction of nibocene dichloride with nucleic acid constituents and amino acids J Med Chem. 39:1996;5012-5016.
29. Hardman, J.G., Limbird, L.E. (Eds.), 1996. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. McGraw-Hill, New York.
30. Hawthorne M.F. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl. 32:1993;950-984.
31. Hjelstuen O.K. Technetium-99m chelators in nuclear medicine. Analyst. 120:1995;863-866.
32. Houghten R.A., Pinilla C., Blondelle S.E., Appel J.R., Dooley C.T., Cuervo J.H. Generation and use of synthetic combinatorial libraries for basic research and drug discovery. Nature. 354:1991;84-86.
33. Howell, S.B. (Ed.), 1991. Platinum and other metal complexes in cancer chemotherapy. Plenum Press, New York.
34. Huang L., Quada J.C., Lown J.W. Design, synthesis, and sequence selective DNA cleavage of functional models of bleomycin. 1. Hybrids incorporating a simple offal-complexing moiety of bleomycin and lexitropsin carriers Bioconjugate Chem. 6:1995;21-33.
35. Jefferson J.W., Greist J.H. Lithium in psychiatry. CNS Drugs. 1:1994;448-464.
36. Judson I., Cerny T., Epelbaum R., Dunlop D., Smyth J., Schaefer B., Roelvink M., Kaplan S., Hanauske A. Phase II trial of the oral platinum complex JM-216 in non-small-cell lung cancer. an EORTC early clinical studies group Ann Oncol. 8:1997;604-606.
37. Jung M., Kerr D.E., Senter P.D. Bio-organometallic chemistry. synthesis and antitumor activity of cobalt carbonyl complexes Arch Pharm (Weinheim, Germany). 330:1997;173-176.
38. Kaim W., Rall J. Copper. a "modern" bioelement Angew Chem Int Ed Engl. 35:1996;43-60.
39. Katti K.V. Recent advances in the chemistry of water-soluble phosphines-catalytic and biomedical aspects. Curr Sci. 70:1996;219-225.
40. Kean W.F., Hart L., Buchanan W.W. Auranofin. Br J Rheumatol. 36:1997;560-572.
41. Keppler, B.K. (Ed.), 1993. Metal complexes in cancer chemotherapy. VCH, New York.
42. Kitamura K., Kiyoi H., Yoshida H., Tobita T., Takeshita A., Ohno R., Naoe T. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia. clinical and basic studies for the next generation Cancer Chemother Pharmac. 40:1997;S36-S41.
43. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 93:1996;8455-8459.
44. Köpf-Maier P. Complexes of metals other than platinum as antitumour agents. Eur J Clin Pharmac. 47:1994;1-16.
45. Köpf-Maier P., Köpf H. Non-platinum-group metal antitumor agents. history, current status, and perspectives Chem Rev. 87:1987;1137-1152.
46. Kumar K., Tweedle M.F. Macrocyclic polyaminocarboxylate complexes of lanthanides as magnetic resonance imaging contrast agents. Pure Appl Chem. 65:1993;515-520.
47. Kuo L.Y., Kanatzidis M.G., Sabat M., Tipton A.L., Marks T.J. Metallocene antitumor agents. solution and solid-state molybdenocene coordination chemistry of DNA constituents J Am Chem Soc. 113:1991;9027-9045.
48. Lee J., Lee S.K., Suh J.S., Yoon M., Song J.H., Lee C.H. Magnetic resonance imaging of the wrist in defining remission of rheumatoid arthritis. J Rheumatol. 24:1997;1303-1308.
49. Lempers E.L.M., Reedijk J. Interactions of platinum amine compounds with sulfur-containing biomolecules and DNA fragments. Adv Inorg Chem. 37:1991;175-217.
50. Lévi F., Misset J.-L., Brienza S., Adam R., Metzger G., Itzakhi M., Caussanel J.-P., Kunstlinger F., Lecouturier S., Descorps-Declère A., Jasmin C., Bismuth H., Reinberg A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer. 69:1992;893-900.
51. Lin J.H., Lu A.Y.H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmac Rev. 49:1997;403-449.
52. Lippard S.J., Berg J.M. Principles of bioinorganic chemistry. 1994;University Science Books, Mill Valley, CA.
53. Maehr H. Combinatorial chemistry in drug research from a new vantage point. Biorg Med Chem. 5:1997;473-491.
54. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance. an overview Immunobiology. 195:1996;129-139.
55. Mechtler L.L., Kinkel P.R. Magnetic resonance imaging in demyelinating, infectious, metabolic, and congenital diseases. Curr Opin Neurol. 6:1993;912-918.
56. Mehta S.C., Lu D.R. Targeted drug delivery for boron neutron capture therapy. Pharmac Res. 13:1996;344-351.
57. Mesner P.W. Jr., Budihardjo I.I., Kaufmann S.H. Chemotherapy-induced apoptosis. Adv Pharmac. 41:1997;461-499.
58. Moebus V.J., Stein R., Kieback D.G., Runnebaum I.B., Sass G., Kreienberg R. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives. Anticancer Res. 17:1997;815-821.
59. 2 with nucleic acid constituents J Med Chem. 37:1994;1936-1941.
60. Myers P.L. Will combinatorial chemistry deliver real medicine? Curr Opin Biotechnol. 8:1997;701-707.
61. Orang-Khadivi K., Pierce B.L., Ollom C.M., Floyd L.J., Siegle R.L., Williams R.F. New magnetic resonance imaging techniques for the detection of breast cancer. Breast Cancer Res Treatment. 32:1994;119-135.
62. Oster M.H., Llobet J.M., Domingo J.L., German J.B., Keen C.L. Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and pro-oxidant effects. Toxicology. 83:1993;115-130.
63. Povirk L.F. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents. bleomycin, neocarzinostatin and other enediynes Mutat Res. 355:1996;71-89.
64. Rainsford K.D., Whitehouse M.W. Antiulcer activity of a slow release zinc complex, zinc monoglycerolate (Glyzinc). J Pharm Pharmac. 44:1992;476-482.
65. Ramurthy S., Miller M.J. Framework-reactive siderophore analogs as potential cell-selective drugs. design and syntheses of trimelamol-based iron chelators J Org Chem. 61:1996;4120-4124.
66. Reedijk J. Heavy metals as useful drugs. Chimia. 51:1997;21-23.
67. Respondek J., Engel J. Organometallics in medicine. Drugs Future. 21(4):1996;391-408.
68. Roberts J.R., Frank Shaw C. III Inhibition of erythrocyte selenium-glutathione peroxidase by Auranofin analogues and metabolites. Biochem Pharmac. 55:1998;1291-1299.
69. Roch-Arveiller M., Huy D.P., Maman L., Giroud J.P., Sorenson J.R. Non-steroidal anti-inflammatory drug-copper complex modulation of polymorphonuclear leukocyte migration. Biochem Pharmac. 39:1990;569-574.
70. Rosenberg B. Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften. 60(9):1973;399-406.
71. Rosenberg B., Van Camp L., Krigas T. Inhibition of cell division in Escherchia coli by electrolysis products from a platinum electrode. Nature. 205:1965;698-699.
72. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds. a new class of potent antitumor agents Nature. 222:1969;385-386.
73. Sadler P.J. Inorganic chemistry and drug design. Adv Inorg Chem. 36:1991;1-48.
74. Sánchez-Delgado R.A., Navarro M., Pérez H., Urbina J.A. Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium and rhodium-chloroquine complexes J Med Chem. 39:1996;1095-1099.
75. Sanderson B.J., Shield A.J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res. 355:1996;41-57.
76. Schilling T., Keppler K.B., Heim M.E., Niebch G., Dietzfelbinger H., Rastetter J., Hanauske A.R. Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Invest New Drugs. 13:1996;327-332.
77. Sekar N., Li J., Shechter Y. Vanadium salts as insulin substitutes. mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research Crit Rev Biochem Mol Biol. 31:1996;339-359.
78. Shaver A., Ng J.B., Hall D.A., Posner B.I. The chemistry of peroxovanadium compounds relevant to insulin mimesis. Mol Cell Biochem. 153:1995;5-15.
79. Shechter Y. Insulin-mimetic effects of vanadate. Diabetes. 39:1990;1-5.
80. Sjoberg S., Carlsson J., Ghaneolhosseini H., Gedda L., Hartman T., Malmquist J., Naeslund C., Olsson P., Tjarks W. Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy. J Neurooncol. 33(1-2):1997;41-52.
81. Soloway A.H., Tjarks W., Barnum B.A., Rong F.-G., Barth R.F., Codogni I.M., Wilson J.G. The chemistry of neutron capture therapy. Chem Rev. 98:1998;1515-1562.
82. Spina E., Perucca E. Newer and older antidepressants. a comparative review of drug interactions CNS Drugs. 2:1994;479-497.
83. Stubbe J., Kozarich J.W., Wu W., Vanderwall D.E. Bleomycins. a structural model for specificity, binding, and double strand cleavage Accounts Chem Res. 29:1996;322-330.
84. Thorp, H.H., Pecoraro, V.L. (Eds.), 1995. Mechanistic bioinorganic chemistry. Advances in Chemistry Series No. 246, American Chemical Society, Washington, DC.
85. Verweij J. New promising anticancer agents in development. what comes next? Cancer Chemother Pharmac. 38(suppl.):1996;S3-S10.
86. Wehrli F., Shaw D., Kneeland J.B. Biological magnetic resonance imaging. principles, methodology, applications:1988;VCH, New York.
87. Weiss R.B., Christian M.C. New cisplatin analogues in development. Drugs. 46:1993;360-377.
88. Woo E.S., Lazo J.S. Nucleocytoplasmic functionality of metallothionein. Cancer Res. 57:1997;4236-4241.
89. Xu R.X., Nettesheim D., Otvos J.D., Petering D.H. NMR determination of the structures of peroxycobalt (III) bleomycin and cobalt (III) bleomycin, products of the aerobic oxidation of cobalt (II) bleomycin by dioxygen. Biochemistry. 33:1994;907-916.
90. Yates A.J., Rodan G.A. Alendronate and osteoporosis. Drug Discovery Today. 3:1998;69-78.
91. Young S.W., Qing F., Harriman A., Sessler J.L., Dow W.C., Mody T.D., Hemmi G.W., Hao Y., Miller R.A. Gadolinium (III) texaphyrin. a tumor selective radiation sensitizer that is detectable by MRI Proc Natl Acad Sci USA. 93:1996;6610-6615.
92. Yuen V.G., Orvig C., McNeill J.H. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium (IV). Can J Physiol Pharmac. 71:1993;263-269.
93. Yuen V.G., Orvig C., McNeill J.H. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can J Physiol Pharmac. 73:1995;55-64.